AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc., bested Keytruda (pembrolizumab) ...

CEO Max Levchin said Affirm expects to be profitable on a GAAP basis in its fiscal fourth quarter of 2025. “The path to reaching any profitability goal is simply more transactions,” Levchin said.

As of Sept. 30, Affirm’s funding capacity was $16.8 billion, resulting in 130% growth over the past three years. Gross merchandise volume growth for the first nine months of the year was 34% ...

Nearly every financial institution has been evaluating generative AI, and Affirm is no exception. CEO Max Levchin teased the buy now/pay later lender's plans for generative AI deployment on the search ...